Catalio Capital Management — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)Maria Fardis(CEO)Cadmus C. Rich(Chief Medical Officer)Elaine Stracker(General Counsel)
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
NextPoint Therapeutics is a biotech company developing first-in-class immuno-oncology therapies, including a T cell engager, an antibody drug conjugate, and a checkpoint inhibitor, using a biomarker-driven approach.
BiotechDeep TechDigital HealthHealthtechMedical DevicesAustin, US
Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)Ivan Cheung(Chief Executive Officer)Leena Gandhi(Chief Medical Officer)Tatiana Novobrantseva(Chief Scientific Officer)Axel Hoos(Director)
Co-investorsCatalio Capital Management, LPMPM BioImpactSanofi VenturesInvusLeaps by BayerSixty Degree Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.